In 2005, CKIA was reported as a specific and potent Cdk4 inhibitor with an IC50 value of 5 nM by VanderWel et al. [17], but in spite of promising properties only marginal examinations concerning inhibition of tumor cell proliferation were performed. The gene discussed is CDK4; the disease is neoplasm.